01-10-2019
105
Global Targeted Drug HER2 Inhibitors for NSCLC Market Status By Manufacturers, Types And Application, History And Forecast to 2025

Scope of the Report:
The global Targeted Drug HER2 Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2025, growing at a CAGR of xx% between 2019 and 2025.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drug HER2 Inhibitors for NSCLC.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2025, with a CAGR of xx%.
This report studies the Targeted Drug HER2 Inhibitors for NSCLC market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drug HER2 Inhibitors for NSCLC market by product type and applications/end industries.

Market Segment by Companies, this report covers
Boehringer-Ingelheim
Roche
Mylan
Biocon

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Afatinib
Trastuzumab
Other

Market Segment by Applications, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC

Table of Contents

Global Targeted Drug HER2 Inhibitors for NSCLC Market Status By Manufacturers, Types And Application, History And Forecast to 2025


Table of Contents

1 Targeted Drug HER2 Inhibitors for NSCLC Market Overview
1.1 Product Overview and Scope of Targeted Drug HER2 Inhibitors for NSCLC
1.2 Classification of Targeted Drug HER2 Inhibitors for NSCLC by Types
1.2.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Comparison by Types (2019-2025)
1.2.2 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Types in 2018
1.2.3 Afatinib
1.2.4 Trastuzumab
1.2.5 Other
1.3 Global Targeted Drug HER2 Inhibitors for NSCLC Market by Application
1.3.1 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2014-2025)
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug HER2 Inhibitors for NSCLC Market by Regions
1.4.1 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2014-2025)
1.4.1 North America (USA, Canada and Mexico) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2014-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2014-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2014-2025)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2014-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2014-2025)
1.5 Global Market Size of Targeted Drug HER2 Inhibitors for NSCLC (2014-2025)
2 Manufacturers Profiles
2.1 Boehringer-Ingelheim
2.1.1 Business Overview
2.1.2 Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Boehringer-Ingelheim Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.2 Roche
2.2.1 Business Overview
2.2.2 Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Roche Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.3 Mylan
2.3.1 Business Overview
2.3.2 Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Mylan Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.4 Biocon
2.4.1 Business Overview
2.4.2 Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biocon Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
3 Global Targeted Drug HER2 Inhibitors for NSCLC Market Competition, by Players
3.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drug HER2 Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug HER2 Inhibitors for NSCLC Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size by Regions
4.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Market Share by Regions
4.2 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.3 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.5 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries
5.1 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2014-2019)
5.2 USA Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5.3 Canada Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5.4 Mexico Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries
6.1 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2014-2019)
6.2 Germany Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.3 UK Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.4 France Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.5 Russia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.6 Italy Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries
7.1 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2014-2019)
7.2 China Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.3 Japan Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.4 Korea Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.5 India Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries
8.1 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2014-2019)
8.2 Brazil Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8.3 Argentina Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8.4 Colombia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Targeted Drug HER2 Inhibitors for NSCLC by Countries
9.1 Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2014-2019)
9.2 Saudi Arabia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.3 UAE Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.4 Egypt Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.5 Nigeria Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.6 South Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
10 Global Targeted Drug HER2 Inhibitors for NSCLC Market Segment by Type
10.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Market Share by Type (2014-2019)
10.2 Global Targeted Drug HER2 Inhibitors for NSCLC Market Forecast by Type (2019-2025)
10.3 Afatinib Revenue Growth Rate (2014-2025)
10.4 Trastuzumab Revenue Growth Rate (2014-2025)
10.5 Other Revenue Growth Rate (2014-2025)
11 Global Targeted Drug HER2 Inhibitors for NSCLC Market Segment by Application
11.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Application (2014-2019)
11.2 Targeted Drug HER2 Inhibitors for NSCLC Market Forecast by Application (2019-2025)
11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
11.4 Adenocarcinoma of NSCLC Revenue Growth (2014-2019)
11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
12 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast (2019-2025)
12.1 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast (2019-2025)
12.2 Global Targeted Drug HER2 Inhibitors for NSCLC Market Forecast by Regions (2019-2025)
12.3 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
12.4 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
12.5 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
12.6 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
12.7 Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source

List of Tables and Figures

Figure Targeted Drug HER2 Inhibitors for NSCLC Picture
Table Product Specifications of Targeted Drug HER2 Inhibitors for NSCLC
Table Global Targeted Drug HER2 Inhibitors for NSCLC and Revenue (Million USD) Market Split by Product Type
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Types in 2018
Figure Afatinib Picture
Figure Trastuzumab Picture
Figure Other Picture
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) by Application (2014-2025)
Figure Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Applications in 2018
Figure Squamous Cell Carcinoma of NSCLC Picture
Figure Adenocarcinoma of NSCLC Picture
Figure Large Cell Carcinoma of NSCLC Picture
Table Global Market Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) Comparison by Regions 2014-2025
Figure North America Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2025)
Figure Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2025)
Figure Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2025)
Figure South America Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2025)
Figure Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2025)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2025)
Table Boehringer-Ingelheim Basic Information, Manufacturing Base and Competitors
Table Boehringer-Ingelheim Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
Table Boehringer-Ingelheim Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Roche Basic Information, Manufacturing Base and Competitors
Table Roche Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
Table Roche Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Mylan Basic Information, Manufacturing Base and Competitors
Table Mylan Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
Table Mylan Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Biocon Basic Information, Manufacturing Base and Competitors
Table Biocon Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
Table Biocon Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) by Players (2014-2019)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Players (2014-2019)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Players in 2017
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Players in 2018
Figure Global Top 5 Players Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share in 2018
Figure Global Top 10 Players Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share in 2018
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) by Regions (2014-2019)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Regions in 2018
Figure North America Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure South America Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2014-2019)
Table North America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure North America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure North America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure USA Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Canada Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Mexico Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Figure Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Germany Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure UK Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure France Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Russia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Italy Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure China Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Japan Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Korea Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure India Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2014-2019)
Table South America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure South America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure South America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Brazil Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Argentina Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Colombia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Saudi Arabia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure UAE Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Egypt Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Nigeria Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure South Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) by Type (2014-2019)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Type (2014-2019)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Type (2014-2019)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Type in 2018
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Forecast by Type (2019-2025)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Market Share Forecast by Type (2019-2025)
Figure Global Afatinib Revenue Growth Rate (2014-2019)
Figure Global Trastuzumab Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2014-2019)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Application (2014-2019)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Application (2014-2019)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Application in 2018
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Forecast by Application (2019-2025)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Market Share Forecast by Application (2019-2025)
Figure Global Squamous Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Adenocarcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Large Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) and Growth Rate Forecast (2019-2025)
Table Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) Forecast by Regions (2019-2025)
Figure Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share Forecast by Regions (2019-2025)
Figure North America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
Figure Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
Figure Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
Figure South America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)
Figure Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2019-2025)

Enquiry Before Buying

*

*
*
*
*
*

Request Sample


*

*
*
*
*
*